Jiangsu Hengrui PharmaceuticalsLtd 향후 성장

Future 기준 점검 2/6

Jiangsu Hengrui PharmaceuticalsLtd (는) 각각 연간 15.8% 및 13.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.7% 로 예상됩니다.

핵심 정보

15.8%

이익 성장률

15.59%

EPS 성장률

Pharmaceuticals 이익 성장	19.8%
매출 성장률	13.6%
향후 자기자본이익률	15.70%
애널리스트 커버리지	Good
마지막 업데이트	11 Nov 2025

최근 향후 성장 업데이트

Jiangsu Hengrui Medicine Co., Ltd. Just Recorded A 6.4% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 02

Recent updates

Jiangsu Hengrui Medicine Co., Ltd. Just Recorded A 6.4% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 02

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Not Lagging Market On Growth Or Pricing

Feb 10

Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?

Jan 19

이익 및 매출 성장 예측

SHSE:600276 - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	42,817	11,619	10,206	11,297	22
12/31/2026	36,878	9,653	8,362	10,351	25
12/31/2025	33,041	8,758	5,977	7,021	25
9/30/2025	30,983	7,468	9,789	11,948	N/A
6/30/2025	30,145	7,355	6,418	8,690	N/A
3/31/2025	29,193	6,842	4,613	6,723	N/A
12/31/2024	27,985	6,337	5,454	7,423	N/A
9/30/2024	25,995	5,448	6,282	7,920	N/A
6/30/2024	25,252	5,426	6,338	7,801	N/A
3/31/2024	23,325	4,432	7,024	8,684	N/A
12/31/2023	22,820	4,302	6,160	7,644	N/A
9/30/2023	22,344	4,207	1,559	3,387	N/A
6/30/2023	22,216	4,095	1,797	3,295	N/A
3/31/2023	21,289	3,909	-346	1,331	N/A
12/31/2022	21,275	3,906	-727	1,265	N/A
9/30/2022	21,652	3,496	1,038	2,908	N/A
6/30/2022	22,836	3,982	1,144	3,566	N/A
3/31/2022	24,455	4,271	2,102	4,168	N/A
12/31/2021	25,906	4,530	2,554	4,219	N/A
9/30/2021	28,520	6,277	1,423	2,944	N/A
6/30/2021	29,723	6,334	412	1,554	N/A
3/31/2021	29,137	6,510	1,290	2,088	N/A
12/31/2020	27,735	6,328	2,878	3,432	N/A
9/30/2020	25,757	5,852	4,574	5,195	N/A
6/30/2020	24,571	5,577	5,177	5,741	N/A
3/31/2020	23,849	5,451	4,388	4,933	N/A
12/31/2019	23,289	5,328	3,255	3,817	N/A
9/30/2019	21,904	4,889	2,831	3,332	N/A
6/30/2019	19,683	4,568	N/A	2,899	N/A
3/31/2019	18,528	4,309	N/A	2,706	N/A
12/31/2018	17,418	4,066	N/A	2,774	N/A
9/30/2018	16,228	3,801	N/A	2,336	N/A
6/30/2018	15,252	3,553	N/A	2,518	N/A
3/31/2018	14,523	3,354	N/A	2,433	N/A
12/31/2017	13,836	3,217	N/A	2,547	N/A
9/30/2017	12,896	2,988	N/A	2,928	N/A
6/30/2017	12,159	2,848	N/A	2,666	N/A
3/31/2017	11,594	2,716	N/A	2,630	N/A
12/31/2016	11,094	2,589	N/A	2,593	N/A
9/30/2016	10,709	2,529	N/A	2,653	N/A
6/30/2016	10,209	2,425	N/A	2,517	N/A
3/31/2016	9,781	2,309	N/A	2,444	N/A
12/31/2015	9,316	2,172	N/A	2,277	N/A
9/30/2015	8,833	1,970	N/A	2,021	N/A
6/30/2015	8,328	1,817	N/A	1,818	N/A
3/31/2015	7,935	1,673	N/A	1,695	N/A
12/31/2014	7,452	1,516	N/A	1,574	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 600276 의 연간 예상 수익 증가율(15.8%)이 saving rate(2.6%)보다 높습니다.

수익 vs 시장: 600276 의 연간 수익(15.8%)이 CN 시장(82.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: 600276 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 600276 의 수익(연간 13.6%)이 CN 시장(연간 9.1%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: 600276 의 수익(연간 13.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 600276의 자본 수익률은 3년 후 15.7%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/12 23:22
종가	2025/11/12 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Jiangsu Hengrui Pharmaceuticals Co.,Ltd는 46명의 분석가가 다루고 있습니다. 이 중 25명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Bo Li	BofA Global Research
Yanan Hou	Bohai Securities Co., Ltd.
Shun Kei Law	CCB International Securities Limited

Jiangsu Hengrui PharmaceuticalsLtd 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 8.4% to CN¥78.31

Consensus EPS estimates increase by 14%

Jiangsu Hengrui Medicine Co., Ltd. Just Recorded A 6.4% EPS Beat: Here's What Analysts Are Forecasting Next

Consensus revenue estimates fall by 10%

Consensus revenue estimates fall by 16%

Price target decreased to CN¥59.01

Recent updates

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Now 23% overvalued after recent price rise

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025

Senior VP & Executive Director recently sold CN¥1.5m worth of stock

IDEAYA Biosciences, Inc. and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-In-Class DLL3 Top1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Senior VP & Executive Director recently sold CN¥1.0m worth of stock

New minor risk - Insider selling

Senior VP & Executive Director recently sold CN¥1.3m worth of stock

Price target increased by 8.4% to CN¥78.31

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 14%

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces an Equity Buyback for CNY 2,000 million worth of its shares.

Now 20% undervalued

Senior VP & Executive Director recently sold CN¥2.1m worth of stock

Hengrui Pharma and Kailera Therapeutics, Inc. Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Senior VP & Executive Director recently sold CN¥1.7m worth of stock

Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Novaliq GmbH Announces Approval as First Treatment for Dry Eye Disease Associated with MGD

Jiangsu Hengrui Medicine Co., Ltd. to Report First Half, 2025 Results on Aug 21, 2025

Jiangsu Hengrui Medicine Co., Ltd.(SHSE:600276) dropped from Shanghai Stock Exchange 180 Value Index

Jiangsu Hengrui Medicine Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 11.373604 billion.

Jiangsu Hengrui Medicine Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 11.373604 billion.

Pacira BioSciences, Inc. Announces Settlement of U.S. Patent Litigation for EXPAREL

Now 21% undervalued

Jiangsu Hengrui Medicine Co., Ltd., Annual General Meeting, Apr 28, 2025

Jiangsu Hengrui Medicine Co., Ltd. Just Recorded A 6.4% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Jiangsu Hengrui Medicine Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Not Lagging Market On Growth Or Pricing

Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Jiangsu Hengrui Medicine Co., Ltd. to Report Fiscal Year 2024 Results on Mar 31, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Jiangsu Hengrui Medicine Co., Ltd. Initiates Phase III Clinical Study of Cs1002/Shr-8068 (Anti-Ctla-4 Monoclonal Antibody) in Combination with Adebrelimab and Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 22%

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Jiangsu Hengrui Medicine Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces an Equity Buyback for CNY 1,200 million worth of its shares.

Jiangsu Hengrui Medicine Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Jiangsu Hengrui Medicine Co., Ltd. to Report Q1, 2024 Results on Apr 18, 2024

Investor sentiment improves as stock rises 16%

Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China

Jiangsu Hengrui Medicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Jiangsu Hengrui Medicine Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) announces an Equity Buyback for CNY 1,200 million worth of its shares.

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.24 in 3Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Consensus revenue estimates fall by 10%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Consensus revenue estimates fall by 16%

Price target decreased to CN¥59.01

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.25 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.22 in 2Q 2020)

Price target decreased to CN¥76.75

Consensus forecasts updated

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of Clinical Trial for Medicine

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.24 in 1Q 2020)

New 90-day low: CN¥89.59

Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the Oncology Market in China